10:16 AM EDT, 04/20/2026 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.

The study, conducted in collaboration with Gilead Sciences ( GILD ) , evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.

The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.

Shares of Arcus Biosciences ( RCUS ) were down 5% in Monday trading.

Price: 23.05, Change: -1.20, Percent Change: -4.95